Selexipag (Uptravi)
The objective of this systematic review is to evaluate the beneficial and harmful effects of selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults (World Health Organization [WHO] FC II or III)
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
September 2017, 2017
|
Series: | CADTH common drug review clinical review report
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references